Israel Active

I reported previously on Israel’s RightHear and its app that enables the visually impaired to navigate shopping malls, hospitals, universities etc. RightHear has since been installed in Israeli supermarket chain Shufersal, launched in the US and is heading for the UK.

The US Biomedical Advanced Research and Development Authority (BARDA) has invested $43 million in Israel’s MediWound to develop its NexoBrid product for the treatment of mustard gas injuries. In 2015 BARDA invested $112 million to help MediWound develop NexoBrid for burns.

I reported previously that the PMD200 pain measurement device from Israel’s Medasense had received European CE Approval. Now, the international Society of Critical Care Medicine has included the innovative technology in its Intensive Care Unit Clinical Practice Guidelines.

Hospitals all over the world use Israeli medical technology. But Israeli Artificial Intelligence (AI) is the next big item. This article highlights Israel’s MedAware (preventing prescription errors), MobiGuide’s Patient Guidance system, Zebra Medical, and AI systems at Israeli hospitals Sheba and Sourasky.

I reported previously on Israel’s Medi-Tate and its non-invasive treatment for benign prostate enlargement.  Now Japan’s Olympus Corporation has invested $20 million in Medi-Tate and will market Medi-Tate’s iTind implant in several countries.

I reported previously on Israel’s PixCell which received a multi-million grant by the EU to help advance its HemoScreen portable blood test.  The US FDA has just approved HemoScreen to sell in the USA. Meanwhile, Israel’s SightDx has launched its OLO blood tester.

I reported previously on Israel’s MedyMatch and its Artificial Intelligent Accipio Ix intracranial hemorrhage detection software.  MedyMatch (renamed MaxQ AI) has now received both FDA and CE approval to sell its systems in both the US and in Europe.

I reported previously on Israel’s Intec Pharma which is developing treatments based on its innovative Accordion technology.  Intec’s COO Nadav Navon provided an update of Intec’s pipeline on ILTV.  Phase 3 trials have now commenced on Intec’s Parkinson’s treatment.

I reported previously about a paraplegic bridegroom who walked down the isle in an Israeli ReWalk exoskeleton. Now a quadriplegic Israeli, Adir, was able to stand next to his bride, Liat, thanks to ReWalk’s latest “UPnRIDE” mobility solution.

Israel’s 2bPrecise takes sources of patient genetic data to help physicians determine the best treatment for individuals. 2bPrecise is partnering with US-based Innovation Institute and Avera Health’s GeneFolio to deliver a pharmacogenomics knowledge base to the point of care.